A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Public ClinicalTrials.gov record NCT05144841. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.
Study identification
- NCT ID
- NCT05144841
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 140 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 8, 2022 (Actual)
- Primary completion
- Apr 21, 2026 (Actual)
- Completion
- Apr 21, 2026 (Actual)
- Last update posted
- May 28, 2026
2022 – 2026
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229) | Orange | California | 92868 | — |
| Innovative Clinical Research Institute ( Site 0202) | Whittier | California | 90603 | — |
| Georgetown University Medical Center ( Site 0204) | Washington D.C. | District of Columbia | 20007 | — |
| Northside Hospital ( Site 0206) | Atlanta | Georgia | 30342 | — |
| University of Chicago Medical Center ( Site 0207) | Chicago | Illinois | 60637 | — |
| Franciscan St. Francis Health ( Site 0225) | Indianapolis | Indiana | 46237 | — |
| University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0211) | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital-Cancer Center Protocol Office ( Site 0203) | Boston | Massachusetts | 02114 | — |
| University of Michigan ( Site 0200) | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute ( Site 0216) | Detroit | Michigan | 48201 | — |
| Saint Louis University Cancer Center ( Site 0209) | St Louis | Missouri | 63110 | — |
| Atlantic Health System Morristown Medical Center ( Site 0213) | Morristown | New Jersey | 07960 | — |
| New York Medical College ( Site 0215) | Valhalla | New York | 10595 | — |
| University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0217) | Cincinnati | Ohio | 45219 | — |
| University Hospitals Cleveland Medical Center ( Site 0222) | Cleveland | Ohio | 44106 | — |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C | Columbus | Ohio | 43210 | — |
| AHN West Penn Hospital ( Site 0212) | Pittsburgh | Pennsylvania | 15224 | — |
| Avera Cancer Institute- Research ( Site 0233) | Sioux Falls | South Dakota | 57105 | — |
| MEDICAL COLLEGE OF WISCONSIN ( Site 0234) | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05144841, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05144841 live on ClinicalTrials.gov.